Abstract
Chimeric antigen receptor (CAR) Tcell therapies are limited by antigen escape and on-target/off-tumor toxicity. In addressing these challenges, Haubner etal. develop an "IF-BETTER" strategy. Their combinatorial chimeric co-stimulatory receptor with an attenuated CAR enhances acute myeloid leukemia (AML) killing while protecting healthy progenitors, highlighting the potential to leverage cooperative CAR designs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have